Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01997281
Other study ID # H-1307-133-508
Secondary ID 0620132990
Status Completed
Phase N/A
First received
Last updated
Start date December 2013
Est. completion date August 2014

Study information

Verified date August 2014
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess whether dietary fiber-enriched cereals effect on postprandial glucose levels and plasma glucagon-like peptide 1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) concentration in patients with type 2 diabetes mellitus.


Description:

Fifteen subjects with type 2 diabetes mellitus will be provided with study meals based on either dietary fiber-enriched cereals or conventional cereals upon two separate admissions in a cross-over fashion. The study meals will be provided at 6 p.m. and 10 p.m. on the day of admission, and 8 a.m. on the next day. A hamburger with coke as mixed meal will be given for lunch at noon on the second day. Blood sampling will be done every 30 minutes from 8 a.m. to 4 p.m. on the second day. The plasma levels of glucose, GLP-1, GIP, insulin, glucagon, and free fatty acid will be measured.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date August 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - type 2 diabetes mellitus - HbA1c 6.5~8.5% - on life style modification or metformin monotherapy at the time of screening Exclusion Criteria: - on sulfonylurea or insulin therapy at the time of screening - allergy to wheat, flour, other cereals or nuts - lactose intolerance - pregnancy / lactation

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
dietary fiber-enriched cereal
provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.) amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.) one serving of steamed egg is added for dinner and breakfast
Other:
conventional cereal
provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.) amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.) one serving (40g) of steamed egg is added for dinner and breakfast

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal To see the changes in the secretion of GLP-1 with dietary fiber enriched cereal, we will calculate the AUC of the plasma total GLP-1 levels. every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Plasma Total GIP Levels After Intake of the Study Meal every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Plasma Glucose Levels After Intake of the Study Meal every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Plasma Insulin Levels After Intake of the Study Meal every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Plasma Glucagon Levels After Intake of the Study Meal every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Serum Free Fatty Acid Levels After Intake of the Study Meal every 30 minutes from 8 a.m. to noon on the second day
Secondary AUC of Plasma Total GIP Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
Secondary AUC of Plasma Glucose Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
Secondary AUC of Plasma Insulin Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
Secondary AUC of Plasma Glucagon Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
Secondary AUC of Serum Free Fatty Acid Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
Secondary AUC of Plasma Total GLP-1 Levels After Lunch every 30 minutes from noon to 4 p.m. on the second day
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A